

Curriculum Vitae

Claudia Staab-Weijnitz PD, Dr. habil. med., Ph.D., Diplom-Biochem. (Univ.)
d.o.b. June 26th, 1975, in Aschaffenburg, Germany

University Education

2018 Habilitation Experimental Pneumology, LMU Munich
2008 Ph.D. in Medical Science, Karolinska Institutet, Stockholm, Sweden
1997-2003 Studies of Biochemistry, University of Bayreuth (University Diploma in Biochemistry, *Diplom-Biochemikerin Univ.*)

Scientific Career

Since 2017 Principal Investigator, Research Group Leader, Comprehensive Pneumology Center (CPC)/Lung Health and Immunity (LHI), Helmholtz Zentrum München, Munich
Since 2022 Member of LMU Ph.D. committee "Medical Research"
2021-2022 Guest Editor for *Frontiers in Medicine*
Since 2020 DZL Academy Board Member
Since 2020 Topic coordinator of Area C "The Mesenchymal Cell: An Active and Powerful Modulator of the Pulmonary Scaffold into the Spatial Context" within the disease area Diffuse Parenchymal Lung Disease (DPLD) of the DZL
Since 2018 Vice-Spokesperson of DFG-funded Research Training Group (RTG) RTG 2338 "Targets in Toxicology", LMU Munich
Since 2018 Editorial Board Member of *Plos One*
Since 2018 Editorial Board Member of *Respiratory Research*
Since 2017 Spokesperson CPC Research School "Lung Biology and Disease"
Since 2017 Committee Member in the American Thoracic Society (ATS) Respiratory Cell and Molecular Biology (RCMB) Assembly's Planning Committee
Since 2016 DZL Principal Investigator
2013-2017 Postdoctoral Research Scientist, Team Leader Comprehensive Pneumology Center (CPC)/Lung Health and Immunity (LHI), Helmholtz Zentrum München, Munich
2012-2013 Scientific Project Manager, Institute for Clinical Radiology, LMU, Munich
2009-2010 Post-Doctoral Research Scientist, Institute for Toxicology and Pharmacology for Natural Scientists, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel
2008-2009 Post-Doctoral Research Scientist, Institute for Environmental Medicine/ Department for Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
2003-2008 Ph.D. candidate, Institute for Environmental Medicine/ Department for Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

Awards and Honors

2015 Best Poster Award for the study „The chaperone FK506-binding protein 10 is a potential novel drug target for idiopathic pulmonary fibrosis“, AIR (Advancing in IPF Research) Symposium, Potsdam
2014-2015 Acceptance as mentee in the Helmholtz Association Mentoring Programme for young female professionals "Taking the lead" (*In Führung gehen*)
2004 Travel Award of the European Tissue Culture Society (ETCS)
1997 Best Apprentice Award (Chemical Laboratory Technician Training, Merck KGaA, Darmstadt), issued by the Chamber of Industry and Commerce, Darmstadt, Germany

Citation Record

Total citations: 1.484; h-index:21; h-index since 2017: 18 (Google Scholar Aug 20th, 2022)

Top-10 selected Publications

Preisendörfer S, Ishikawa Y, Hennen E, Winklmeier S, Schupp JC, Knüppel L, Fernandez IE, Binzenhöfer L, Flatley A, Juan-Guardela BM, Ruppert R, Guenther A, Frankenberger M, Hatz RA, Kneidinger N, Behr J, Feederle R, Schepers A, Hilgendorff A, Kaminski N, Meinel E, Bächinger HP, Eickelberg O and **Staab-Weijnitz CA** (2022). FK506-binding protein 11 is a novel plasma cell-specific antibody folding catalyst with increased expression in idiopathic pulmonary fibrosis. **Cells**, 11(8):1341

Mastalerz M, Dick E, Chakraborty AA, Hennen E, Schamberger AC, Schröppel A, Lindner M, Hatz R, Behr J, Hilgendorff A, Schmid O, **Staab-Weijnitz CA** (2022). Validation of in vitro models for smoke exposure of primary human bronchial epithelial cells. **Am J Physiol Lung Cell Mol Physiol**, 322(1):L129-L148

Merl-Pham J, Basak T, Knüppel L, Ramanujam D, Athanason M, Behr J, Engelhardt S, Eickelberg O, Hauck SM, Vanacore R, **Staab-Weijnitz CA** (2019). Quantitative proteomic profiling of extracellular matrix and site-specific collagen post-translational modifications in an in vitro model of lung fibrosis. **Matrix Biology Plus**, 1: 100005

Knüppel L, Heinzelmann K, Lindner M, Hatz R, Behr J, Eickelberg O, **Staab-Weijnitz CA** (2018). FK506-binding protein 10 (FKBP10) regulates lung fibroblast migration via collagen VI synthesis. **Respir Res**, 19(1):67

Schiller HB, Mayr CH, Leuschner G, Strunz M, **Staab-Weijnitz C**, Preisendörfer S, Eckes B, Moinzadeh P, Krieg T, Schwartz DA, Hatz RA, Behr J, Mann M, Eickelberg O (2017). Deep Proteome Profiling Reveals Common Prevalence of MZB1-Positive Plasma B Cells in Human Lung and Skin Fibrosis. **Am J Respir Crit Care Med**, 196(10):1298-1310

Alsafadi HN, **Staab-Weijnitz CA**, Lehmann M, Lindner M, Peschel B, Königshoff M, Wagner DE (2017). An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices. **Am J Physiol Lung Cell Mol Physiol**, 312(6):L896-L902

Knüppel L, Ishikawa Y, Aichler M, Heinzelmann K, Hatz R, Behr J, Walch A, Bächinger HP, Eickelberg O, **Staab-Weijnitz CA** (2017). A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly. **Am J Respir Cell Mol Biol**, 57(1):77-90

Schamberger AC, Schiller HB, Fernandez IE, Sterclova M, Heinzelmann K, Hennen E, Hatz R, Behr J, Vašáková M, Mann M, Eickelberg O, **Staab-Weijnitz CA** (2016). Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in interstitial lung disease. **Sci Rep**, 6:29952

Staab-Weijnitz CA, Fernandez IE, Knüppel L, Maul J, Heinzelmann K, Juan-Guardela BM, Hennen E, Preissler G, Winter H, Neurohr C, Hatz R, Lindner M, Behr J, Kaminski N, Eickelberg O (2015). FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis. **Am J Respir Crit Care Med**, 192(4):455-67

Schamberger AC, **Staab-Weijnitz CA**, Mise-Racek N, Eickelberg O (2015). Cigarette smoke alters primary human bronchial epithelial cell differentiation at the air-liquid interface. **Sci Rep**, 5:8163